抑郁症的分子生物学探究

陈 紫盺¹, 刘 祚铭¹, 石 欣雨¹, 王 子豪¹, 王 倩¹, 陈 小静¹, 张 蕊²
1、沈阳药科大学 110016
2、通讯作者沈阳药科大学 110016

摘要

目的：抑郁症目前是一种常见的精神障碍，目前常用的研究手段没有办法研究出抑郁症的研究机制。我们通过不断地查阅文献，解释了抑郁症的分子生物学方向的机制。同时我们又列举了常见的几种基于分子生物学机制的药物。

关键词

抑郁症；生物学机制；

参考

[1] 1. Dean J, Keshavan M.Asian J Psychiatr. 2017 Jun;27:101-111. doi: 10.1016/j.ajp.2017.01.025. Epub 2017 Jan 29. [2] Fox ME, Lobo MK. The molecular and cellular mechanisms of depression: a focus on reward circuitry. Mol Psychiatry. 2019 Dec;24(12):1798-1815. doi: 10.1038/s41380-019-0415-3. Epub 2019 Apr 9. PMID: 30967681; PMCID: PMC6785351. [3]Chamberlain, S. R., & Baldwin, D. S. (2021). Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. CNS Drugs, 35(7), 703–716. [4]Suchting Robert et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis[J]. Journal of Affective Disorders, 2021, [5]Dosenovic S, Jelicic Kadic A, Miljanovic M, Biocic M, Boric K, Cavar M, Markovina N, Vucic K, Puljak L. Interventions for Neuropathic Pain: An Overview of Systematic Reviews. Anesth Analg. 2017 Aug;125(2):643-652. doi: 10.1213/ANE.0000000000001998. PMID: 28731977. [6]赵婕，谢健．抑郁症和慢性疼痛的药物治疗［J］．医药导报，2019，38(5) :622－625． [7] Li, H.-D.; Zhu, Y.-G.; Yi, Q.-H. Foreign Medical Sciences Section of Pharmacy 1998, 25, 228 (in Chinese). (李焕德, 朱运贵, 易清华, 国外医学药学分册, 1998, 25, 228.) [8] Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018 Jul;19(10):1057-1070. doi:10.1080/14656566.2018.1491966. PMID: 30056792; PMCID: PMC6340395.